Methods Relevant articles for this review were retrieved from Google Scholar, Clinicaltrials.
gov., and PubMed using the terms “non-small-cell lung cancer”,“NSCLC”,“neoadjuvant”,“ …

Objective Progress in neoadjuvant therapy for resectable nonsmall cell lung cancer (NSCLC
1) has been stagnant. There have been great achievements in immunotherapy for advanced …

Background In recent years, a series of clinical trials have explored the application of
neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer …

Background Neoadjuvant immunochemotherapy may benefit patients with non-small cell
lung cancer (NSCLC), but its impact requires further investigation. Methods A meta-analysis …

Background Neoadjuvant immunotherapy (nIT) is a rapidly emerging paradigm for
advanced resectable non‐small cell lung cancer (NSCLC). The objectives of this …

Objective. Immunotherapy has shown better efficacy and less toxicity than chemotherapy in
the treatment of non‐small‐cell lung cancer (NSCLC) at advanced stage. This study …

Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and
locally advanced non-small-cell lung cancer (NSCLC). Antibodies blocking inhibitory …

Background It remains uncertain whether neoadjuvant immune checkpoint inhibitor (nICI) is
superior to neoadjuvant chemotherapy (nCT) in resectable non-small cell lung cancer. In …

Simple Summary The benefit of neoadjuvant chemoimmunotherapy was compared with
chemotherapy for localized NSCLC in several trials. We conducted a systematic review and …

Lung cancer is one of the most common malignant tumors and it is the leading cause of
cancer-related mortality worldwide. For early-stage Non-Small Cell Lung Cancer (NSCLC) …